3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
4
Completed
4
Unknown
1
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Lymphoid
1
Breast
1
Conditions
Motor Activity
22
Breast Neoplasms
14
Neoplasms
9
Fatigue
5
Prostatic Neoplasms
4
Obesity
4
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Peripheral Nervous System Diseases
2
Overweight
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lung Neoplasms
2
Cognitive Dysfunction
2
Cardiovascular Diseases
2
Urogenital Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Smoking
1
Skin Neoplasms
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Ovarian Neoplasms
1
Osteolysis
1
Non-alcoholic Fatty Liver Disease
1
Neuroectodermal Tumors, Primitive
1
Neurocognitive Disorders
1
Multiple Endocrine Neoplasia Type 1
1
Metabolic Syndrome
1
Interventions
Cyclophosphamide
26
Rituximab
22
Biopsy
17
Specimen Handling
16
Prednisone
14
Magnetic Resonance Spectroscopy
14
Doxorubicin
14
fludarabine
12
Vincristine
12
fludarabine phosphate
9
Etoposide
7
Bendamustine Hydrochloride
7
Tacrolimus
6
Nuclear Medicine Department, Hospital
6
Melphalan
6
trametinib
5
acalabrutinib
5
X-Rays
5
Whole-Body Irradiation
5
Radiotherapy
5
Mycophenolic Acid
5
Crizotinib
5
pembrolizumab
4
copanlisib
4
Prednisolone
4
Mesna
4
Lenalidomide
4
Dexamethasone
4
Cytarabine
4
Busulfan
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma
×
Exercise
×
Clear all
NCT05509751
2026-04-28
SOAR
University of Toronto
Phase NA
Active not recruiting
60 enrolled